MX2010009649A - Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. - Google Patents
Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.Info
- Publication number
- MX2010009649A MX2010009649A MX2010009649A MX2010009649A MX2010009649A MX 2010009649 A MX2010009649 A MX 2010009649A MX 2010009649 A MX2010009649 A MX 2010009649A MX 2010009649 A MX2010009649 A MX 2010009649A MX 2010009649 A MX2010009649 A MX 2010009649A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pain
- formula
- disease
- bis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title description 10
- 239000005557 antagonist Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 108010038912 Retinoid X Receptors Proteins 0.000 claims abstract description 22
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims abstract 3
- 208000002193 Pain Diseases 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 230000036407 pain Effects 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 208000013403 hyperactivity Diseases 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 231100000876 cognitive deterioration Toxicity 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 30
- 102000034527 Retinoid X Receptors Human genes 0.000 description 19
- 230000010412 perfusion Effects 0.000 description 19
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 210000004326 gyrus cinguli Anatomy 0.000 description 11
- 230000013016 learning Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000003935 attention Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000036992 cognitive tasks Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000008451 emotion Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- WCRBPHCZIAXTAX-UHFFFAOYSA-N 1h-imidazole;pyridazine Chemical class C1=CNC=N1.C1=CC=NN=C1 WCRBPHCZIAXTAX-UHFFFAOYSA-N 0.000 description 4
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 4
- 101100494761 Homo sapiens NEDD9 gene Proteins 0.000 description 4
- 102000038100 NR2 subfamily Human genes 0.000 description 4
- 108020002076 NR2 subfamily Proteins 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000009593 lumbar puncture Methods 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000037324 pain perception Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 210000004129 prosencephalon Anatomy 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000027928 long-term synaptic potentiation Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 230000002360 prefrontal effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- BOVUHBFXPNLTKF-UHFFFAOYSA-N 5-[3-(difluoromethyl)-4-fluorophenyl]-3-[(2-methylimidazol-1-yl)methyl]pyridazine Chemical compound CC1=NC=CN1CC1=CC(C=2C=C(C(F)=CC=2)C(F)F)=CN=N1 BOVUHBFXPNLTKF-UHFFFAOYSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 102000034570 NR1 subfamily Human genes 0.000 description 1
- 108020001305 NR1 subfamily Proteins 0.000 description 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006390 fear memory Effects 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000010387 memory retrieval Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 230000009486 mnemonic function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4008708P | 2008-03-27 | 2008-03-27 | |
| PCT/EP2009/002241 WO2009118187A1 (en) | 2008-03-27 | 2009-03-26 | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010009649A true MX2010009649A (es) | 2010-12-17 |
Family
ID=40910288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010009649A MX2010009649A (es) | 2008-03-27 | 2009-03-26 | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110053951A1 (enExample) |
| EP (1) | EP2254580A1 (enExample) |
| JP (3) | JP2011516417A (enExample) |
| KR (1) | KR20100135847A (enExample) |
| CN (1) | CN101977606A (enExample) |
| AU (1) | AU2009228660B2 (enExample) |
| BR (1) | BRPI0909378A2 (enExample) |
| CA (1) | CA2719749A1 (enExample) |
| IL (1) | IL207835A0 (enExample) |
| MX (1) | MX2010009649A (enExample) |
| NZ (1) | NZ588698A (enExample) |
| RU (1) | RU2499598C2 (enExample) |
| WO (1) | WO2009118187A1 (enExample) |
| ZA (1) | ZA201006587B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9387212B2 (en) | 2012-04-20 | 2016-07-12 | Ucb Biopharma Sprl | Methods for treating Parkinson's disease |
| US11232319B2 (en) * | 2014-05-16 | 2022-01-25 | The Trustees Of The University Of Pennsylvania | Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models |
| US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| HUE049277T2 (hu) | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Triazolok mint NR2B receptor inhibitorok |
| EP3303323B1 (en) * | 2015-06-01 | 2020-01-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| HRP20200410T1 (hr) | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| EP3544610A1 (en) | 2016-11-22 | 2019-10-02 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| US10732235B2 (en) * | 2018-03-29 | 2020-08-04 | Siemens Healthcare Gmbh | Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping |
| EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| EP3983074A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyridine carbamates and their use as glun2b receptor modulators |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| MX2021015500A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. |
| MX2021015506A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b. |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| CA3143102A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997032581A1 (en) * | 1996-03-08 | 1997-09-12 | F. Hoffmann-La Roche Ag | Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
| TWI254043B (en) * | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| DE60007697T2 (de) * | 1999-07-21 | 2004-12-09 | F. Hoffmann-La Roche Ag | Triazolderivate |
| AU2001273942B2 (en) * | 2000-04-20 | 2005-09-01 | F. Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders |
| US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| US7022882B2 (en) * | 2000-10-06 | 2006-04-04 | The Regents Of The University Of California | NMDA receptor channel blocker with neuroprotective activity |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| JP2009503520A (ja) * | 2005-07-29 | 2009-01-29 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ベータアミロイド受容体及びその使用 |
-
2009
- 2009-03-26 KR KR1020107023896A patent/KR20100135847A/ko not_active Ceased
- 2009-03-26 CA CA2719749A patent/CA2719749A1/en not_active Abandoned
- 2009-03-26 RU RU2010143864/15A patent/RU2499598C2/ru not_active IP Right Cessation
- 2009-03-26 AU AU2009228660A patent/AU2009228660B2/en not_active Ceased
- 2009-03-26 MX MX2010009649A patent/MX2010009649A/es active IP Right Grant
- 2009-03-26 NZ NZ588698A patent/NZ588698A/en not_active IP Right Cessation
- 2009-03-26 US US12/919,804 patent/US20110053951A1/en not_active Abandoned
- 2009-03-26 BR BRPI0909378A patent/BRPI0909378A2/pt not_active IP Right Cessation
- 2009-03-26 JP JP2011501153A patent/JP2011516417A/ja active Pending
- 2009-03-26 WO PCT/EP2009/002241 patent/WO2009118187A1/en not_active Ceased
- 2009-03-26 CN CN2009801104274A patent/CN101977606A/zh active Pending
- 2009-03-26 EP EP09724248A patent/EP2254580A1/en not_active Withdrawn
-
2010
- 2010-08-26 IL IL207835A patent/IL207835A0/en unknown
- 2010-09-14 ZA ZA2010/06587A patent/ZA201006587B/en unknown
-
2014
- 2014-02-05 JP JP2014020051A patent/JP2014098018A/ja active Pending
-
2015
- 2015-12-03 JP JP2015236571A patent/JP2016094430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201006587B (en) | 2012-02-29 |
| JP2011516417A (ja) | 2011-05-26 |
| CN101977606A (zh) | 2011-02-16 |
| IL207835A0 (en) | 2010-12-30 |
| RU2010143864A (ru) | 2012-05-10 |
| CA2719749A1 (en) | 2009-10-01 |
| NZ588698A (en) | 2012-06-29 |
| JP2016094430A (ja) | 2016-05-26 |
| US20110053951A1 (en) | 2011-03-03 |
| RU2499598C2 (ru) | 2013-11-27 |
| EP2254580A1 (en) | 2010-12-01 |
| WO2009118187A1 (en) | 2009-10-01 |
| KR20100135847A (ko) | 2010-12-27 |
| AU2009228660A1 (en) | 2009-10-01 |
| BRPI0909378A2 (pt) | 2015-10-06 |
| JP2014098018A (ja) | 2014-05-29 |
| AU2009228660B2 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010009649A (es) | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. | |
| Yu et al. | Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease | |
| Vuyk | Pharmacodynamics in the elderly | |
| Lei et al. | NMDA receptors in the anterior cingulate cortex mediate pain-related aversion | |
| Zhao et al. | Quantitative evaluation of neuronal loss in the dorsal hippocampus in rats with long-term pilocarpine seizures | |
| Savage et al. | Translational rodent models of Korsakoff syndrome reveal the critical neuroanatomical substrates of memory dysfunction and recovery | |
| Pan et al. | Activating autophagy in hippocampal cells alleviates the morphine-induced memory impairment | |
| US20090197969A1 (en) | Method of reducing brain cell damage or death | |
| Alkislar et al. | Inhaled cannabis suppresses chemotherapy-induced neuropathic nociception by decoupling the raphe nucleus: a functional imaging study in rats | |
| Gass et al. | Antagonism at the NR2B subunit of NMDA receptors induces increased connectivity of the prefrontal and subcortical regions regulating reward behavior | |
| Jeong et al. | Investigation of the pruritus‐induced functional activity in the rat brain using manganese‐enhanced MRI | |
| Masuda et al. | Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease | |
| Baizer | Functional and neuropathological evidence for a role of the brainstem in autism | |
| Woehrle et al. | Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation | |
| Taleb et al. | New application of an old drug proparacaine in treating epilepsy via liposomal hydrogel formulation | |
| Zhang et al. | Miconazole alleviates peripheral nerve crush injury by mediating a macrophage phenotype change through the NF‐κB pathway | |
| Sullivan et al. | Commentary on “Increased MCP-1 and Microglia in Various regions of Human Alcoholic Brain” | |
| Sun et al. | Enhancing glymphatic fluid transport by pan-adrenergic inhibition suppresses epileptogenesis in male mice | |
| Sui et al. | Scorpion venom heat-resistant synthesized peptide ameliorates epileptic seizures and imparts neuroprotection in rats mediated by NMDA receptors | |
| Chung et al. | Postsynaptic nicotinic acetylcholine receptors facilitate excitation of developing CA1 pyramidal neurons | |
| Kertmen et al. | The effect of thiocolchicoside on cerebral vasospasm following experimental subarachnoid hemorrhage in the rabbit | |
| Sekar et al. | Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging | |
| DE60004473T2 (de) | Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen | |
| Xia et al. | Ulinastatin modulates TRPM4 expression and apoptosis to mitigate cognitive dysfunction in aged perioperative neurocognitive disorder rats | |
| Paoletti | Focusing on altered neuronal networks to fight early deficits in a mouse model of Alzheimer’s Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: ITALMATCH CHEMICALS SPA |
|
| FG | Grant or registration |